Study of MK-3120 for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, MK-3120, for people with a specific type of bladder cancer that hasn't spread into the muscle. It is for patients who either haven't had BCG treatment before or have had BCG treatment and their cancer came back more than 12 months but within 2 years after the last dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bladder cancer called carcinoma in situ, with or without other high-risk non-muscle invasive bladder cancer.
- Your most recent bladder tumor removal surgery must have been within the last 12 weeks and showed high-risk features.
- You either have never had BCG treatment or had it more than 2 years ago with a complete response, or you had BCG and your cancer came back between 12 and 24 months after the last dose.
- If you have HIV, it must be well-controlled with medication.
- If you have hepatitis B or C, your viral load must be undetectable and you may need to be on treatment.
- You cannot have other cancers that are growing or need treatment, active infections, severe heart or eye problems, or a history of lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new drug (IAP0971) given with BCG, a standard bladder treatment, to see if it helps people with high-risk bladder cancer that hasn't spread into the muscle. You may join if you've already tried BCG and it didn't work, and you're not having your bladder removed.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.